|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC00657 |
Gene summary for LINC00657 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC00657 | Gene ID | 647979 |
| Gene name | non-coding RNA activated by DNA damage | |
| Gene Alias | LINC00657 | |
| Cytomap | 20q11.23 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 647979 | LINC00657 | P28T-E | Human | Esophagus | ESCC | 1.01e-76 | 1.31e+00 | 0.1149 |
| 647979 | LINC00657 | P30T-E | Human | Esophagus | ESCC | 9.20e-66 | 2.18e+00 | 0.137 |
| 647979 | LINC00657 | P31T-E | Human | Esophagus | ESCC | 3.21e-118 | 1.85e+00 | 0.1251 |
| 647979 | LINC00657 | P32T-E | Human | Esophagus | ESCC | 1.73e-78 | 1.44e+00 | 0.1666 |
| 647979 | LINC00657 | P36T-E | Human | Esophagus | ESCC | 1.77e-65 | 1.69e+00 | 0.1187 |
| 647979 | LINC00657 | P37T-E | Human | Esophagus | ESCC | 6.87e-58 | 1.15e+00 | 0.1371 |
| 647979 | LINC00657 | P38T-E | Human | Esophagus | ESCC | 1.46e-20 | 7.90e-01 | 0.127 |
| 647979 | LINC00657 | P39T-E | Human | Esophagus | ESCC | 6.31e-48 | 1.07e+00 | 0.0894 |
| 647979 | LINC00657 | P40T-E | Human | Esophagus | ESCC | 1.41e-45 | 1.13e+00 | 0.109 |
| 647979 | LINC00657 | P42T-E | Human | Esophagus | ESCC | 2.94e-58 | 1.27e+00 | 0.1175 |
| 647979 | LINC00657 | P44T-E | Human | Esophagus | ESCC | 2.00e-45 | 1.13e+00 | 0.1096 |
| 647979 | LINC00657 | P47T-E | Human | Esophagus | ESCC | 1.39e-84 | 1.56e+00 | 0.1067 |
| 647979 | LINC00657 | P48T-E | Human | Esophagus | ESCC | 7.92e-69 | 1.20e+00 | 0.0959 |
| 647979 | LINC00657 | P49T-E | Human | Esophagus | ESCC | 6.66e-35 | 1.85e+00 | 0.1768 |
| 647979 | LINC00657 | P52T-E | Human | Esophagus | ESCC | 9.62e-68 | 1.42e+00 | 0.1555 |
| 647979 | LINC00657 | P54T-E | Human | Esophagus | ESCC | 1.52e-55 | 1.17e+00 | 0.0975 |
| 647979 | LINC00657 | P56T-E | Human | Esophagus | ESCC | 2.03e-26 | 2.64e+00 | 0.1613 |
| 647979 | LINC00657 | P57T-E | Human | Esophagus | ESCC | 1.71e-81 | 1.37e+00 | 0.0926 |
| 647979 | LINC00657 | P61T-E | Human | Esophagus | ESCC | 7.13e-70 | 1.54e+00 | 0.099 |
| 647979 | LINC00657 | P62T-E | Human | Esophagus | ESCC | 2.82e-109 | 1.83e+00 | 0.1302 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |